Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

In part 1 of 4 from this episode, the discussion focuses on the backgrounds of guests Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir.

Kidney Compass: Introducing the PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir

This 4-part episode focuses on the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis treatment.

Kidney Compass: The PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir

As announced by NovelMed on December 2, 2024, the FDA has granted IND clearance for Ruxoprubart to commence an efficacy trial for the treatment of IgAN.

FDA Clears Initiation of Phase 2 Efficacy Trial for Ruxoprubart in IgAN

Initiation of population-wide CKD screening followed by conventional CKD treatment plus SGLT2 inhibitors at 55 years of age was cost-effective.

Population-Wide CKD Screening Cost-Effective When Started At Age 55 Years, Study Finds

Treatment with the novel selective endothelin receptor type A antagonist alongside standard care reduced UPCR in patients with IgAN in a phase 2 trial.

Phase 2 Data Highlight SC0062’s Dose-Dependent Impact on Proteinuria in IgA Nephropathy

The study is one of the first to report United States IgAN incidence based on a large racially and ethnically diverse cohort.

Racial, Ethnic IgA Nephropathy Stratification Provides New Insight Into US Incidence

This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.

Nephrology Month in Review: October 2024

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan. 

How AFFINITY Informs on Potential of Atrasentan, with Jonathan Barratt, MD, PhD

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.

Felzartamab Updates in IgAN from Kidney Week 2024, with Jonathan Barratt, MD, PhD

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.

Long-term Options for IgAN Management, with Jonathan Barratt, MD, PhD

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.